Showing 221 - 240 results of 248 for search '"macular degeneration"', query time: 0.08s Refine Results
  1. 221

    Clinical experience with recombinant prourokinase for complex retinal diseases in type 2 diabetes by L.K. Moshetova, Yu.B. Slonimsky, I.V. Vorobyeva, A. Dgebuadze, O.V. Agafonova, E.P. Delver, A.A. Belogurov

    Published 2019-07-01
    “…., diabetic retinopathy, hypertensive retinopathy, “wet” age-related macular degeneration (AMD) with hemorrhages in type 2 diabetes) using recombinant prourokinase by dynamic retinal changes and tear levels of vascular endothelial growth factor (VEGF-A).…”
    Get full text
    Article
  2. 222

    High-coverage whole-genome sequencing of a Jakun individual from the “Orang Asli” Proto-Malay subtribe from Peninsular Malaysia by Wai-Sum Yap, Alvin Cengnata, Woei-Yuh Saw, Thuhairah Abdul Rahman, Yik-Ying Teo, Renee Lay-Hong Lim, Boon-Peng Hoh

    Published 2025-01-01
    “…Some of these variants are associated with age-related macular degeneration, atrial fibrillation, and HDL cholesterol level. …”
    Get full text
    Article
  3. 223

    میزان سرب خون در بیماران مبتلا به دژنراسیون ماکولا وابسته به سن by مینا پولادوند, مصطفی فقهی, محمد ملک احمدی, فریدون فرهی, زهرا رمضانی, علی شهسواری, پردیس تولائی نژاد

    Published 2024-11-01
    “…مقاله پژوهشیمقدمه: هدف از این مطالعه، ارزیابی سطح سرب خون در بیماران مبتلا به دژنراسیون ماکولا وابسته به سن (Age-related macular degeneration ) AMD بود.روش‌ها: این مطالعه‌ی مورد- شاهدی، بر روی بیماران مبتلا به AMD و افراد سالم در شهر اهواز استان خوزستان در ایران انجام شد. …”
    Get full text
    Article
  4. 224

    Luteolin Attenuates IL-1β-Induced THP-1 Adhesion to ARPE-19 Cells via Suppression of NF-κB and MAPK Pathways by Wen-Chung Huang, Chian-Jiun Liou, Szu-Chuan Shen, Sindy Hu, Chien-Yu Hsiao, Shu-Ju Wu

    Published 2020-01-01
    “…Inflammation is a critical mediator in retinal degeneration (RD) diseases, including age-related macular degeneration (AMD), and RD progression may be prevented through anti-inflammatory activity in RPE cells. …”
    Get full text
    Article
  5. 225

    Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting by Anne-Laurence Best, Franck Fajnkuchen, Sylvia Nghiem-Buffet, Typhaine Grenet, Gabriel Quentel, Corinne Delahaye-Mazza, Salomon Y. Cohen, Audrey Giocanti-Aurégan

    Published 2018-01-01
    “…Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results. Seventy-two eyes of 55 consecutive DME patients were included. …”
    Get full text
    Article
  6. 226

    Pooled Multicenter Safety Analysis of Lupin’s Intravitreal Biosimilar Ranibizumab (Ranieyes) in Chorioretinal Vascular Diseases by Debdulal Chakraborty, Tushar Kanti Sinha, Sourav Sinha, Aniruddha Maiti, Angshuman Mukherjee, Krishnendu Nandi, Sudipta Das, Saptorshi Majumdar, Dinesh Rungta, Ranabir Bhattacharya

    Published 2024-11-01
    “…Abstract Introduction This study aims to evaluate the ocular and systemic safety profiles of intravitreal biosimilar ranibizumab Ranieyes (Lupin Pharmaceuticals, Mumbai, India) in real-world clinical settings across multiple chorioretinal vascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) in adults. …”
    Get full text
    Article
  7. 227

    The Association of Retinal Disease with Vision Impairment and Functional Status in Medicare Patients by Vincent Garmo, Xiaohui Zhao, Carmen D. Ng, Aimee Near, Tania Banerji, Keiko Wada, Gary Oderda, Diana Brixner, Joseph Biskupiak, Ferhina S. Ali, Archad M. Khanani, Alicia Menezes, Ibrahim M. Abbass

    Published 2024-03-01
    “…**Background:** The association of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) with functional status in the general Medicare population are not well established. …”
    Get full text
    Article
  8. 228

    Vision impairment and differential access to eye health services in Aotearoa New Zealand: a scoping review by Matire Harwood, Jacqueline Ramke, Joanna Black, Himal Kandel, Jaymie Tingkham Rogers, Ben Wilkinson

    Published 2024-06-01
    “…Closing the evidence gap identified for refractive error, glaucoma and macular degeneration service coverage could be a priority for future research. …”
    Get full text
    Article
  9. 229

    Pirfenidone Alleviates Choroidal Neovascular Fibrosis through TGF-β/Smad Signaling Pathway by Chuang Gao, Xin Cao, Lili Huang, Yueqi Bao, Tao Li, Yue Di, Liucheng Wu, Yu Song

    Published 2021-01-01
    “…The results of this study suggest that TGF-β2 represents a target to prevent or treat choroidal neovascular fibrosis, and PFD may provide an alternative to traditional methods for Wet Age-related macular degeneration (wAMD) treatment.…”
    Get full text
    Article
  10. 230

    The Prevalence of Undiagnosed Age-Related Sight-Threatening Diseases in Self-Proclaimed Healthy Individuals by Sophie Lemmens, João Barbosa Breda, Karel Van Keer, Tine Jacobs, Ruben Van Landeghem, Patrick De Boever, Ingeborg Stalmans

    Published 2020-01-01
    “…Age-related conditions such as glaucoma, age-related macular degeneration, diabetic retinopathy, and cataract have become the major cause of visual impairment and blindness in high-income countries. …”
    Get full text
    Article
  11. 231

    Multi-omic spatial effects on high-resolution AI-derived retinal thickness by V. E. Jackson, Y. Wu, R. Bonelli, J. P. Owen, L. W. Scott, S. Farashi, Y. Kihara, M. L. Gantner, C. Egan, K. M. Williams, B. R. E. Ansell, A. Tufail, A. Y. Lee, M. Bahlo

    Published 2025-02-01
    “…The macula is disproportionately affected by high disease burden retinal disorders such as age-related macular degeneration and diabetic retinopathy, which both involve metabolic dysregulation. …”
    Get full text
    Article
  12. 232

    Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab by Alper Bilgic, Laurent Kodjikian, Jay Chhablani, Anand Sudhalkar, Megha Trivedi, Viraj Vasavada, Vaishali Vasavada, Shail Vasavada, Samaresh Srivastava, Deepak Bhojwani, Aditya Sudhalkar

    Published 2020-01-01
    “…Patients. 789 patients (1021 eyes; 602 males) enrolled in T&E using aflibercept/ranibizumab for diabetic macular edema (DME), wet age-related macular degeneration (AMD), or macular edema in retinal vein occlusion (RVO). …”
    Get full text
    Article
  13. 233

    Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection by Ruamviboonsuk V, Kongwattananon W, Chuaypen N

    Published 2025-02-01
    “…Varis Ruamviboonsuk,1,2 Wijak Kongwattananon,1,3 Natthaya Chuaypen4 1Department of Ophthalmology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 2Medical Science Program, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 4Metabolic Diseases in Gut and Urinary System Research Unit (MeDGURU), Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandCorrespondence: Wijak Kongwattananon, Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand, Tel +662 256 4000, Email wijak.k@chula.ac.thPurpose: Intravitreal brolucizumab, approved for neovascular age-related macular degeneration (nAMD), may trigger immune responses leading to intraocular inflammation (IOI) by increasing pro-inflammatory cytokines. …”
    Get full text
    Article
  14. 234

    Development and progression association of various ophthalmic pathologies with the gut microbiome state (literature review) by G.N. Rezbaeva, A.E. Babushkin, O.I. Orenburkina, I.A. Gimranova

    Published 2023-11-01
    “…For instance, dry eye syndrome, especially chronic progressive ophthalmic pathology, such as diabetic retinopathy, glaucoma, age-related macular degeneration, etc. </p> <p> <b>Keywords: </b>microbiome, gut microbiota dysbiosis, association with eye diseases, development of treatment techniques. …”
    Get full text
    Article
  15. 235

    Perspectives of proteomic analysis in ophthalmology by A.A. Krylova, A.V. Zakharchuk, O.I. Krivosheina, S.I. Pekov, I.A. Popov

    Published 2023-11-01
    “…The results of proteomic mapping of tear and aqueous humor in dry eye disease, keratoconus, glaucoma, cataract, age-related macular degeneration, and diabetic retinopathy are described. …”
    Get full text
    Article
  16. 236

    Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes by Jennifer Cattaneo, Paolo Forte, Giovanni Forte, Chiara M. Eandi

    Published 2025-01-01
    “…Clinical records of treatment-naïve and non-responder switch patients presenting T1 MNV secondary to neovascular age-related macular degeneration (nAMD) from September 2022 to March 2023 were reviewed. …”
    Get full text
    Article
  17. 237

    Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe by Barakat MR, Kwong Jr HM, Marcon G, O'Leary OE, Paris LP, Schneider P, Tang Y, Graff JM

    Published 2025-02-01
    “…., San Francisco, CA, USA; 6Barnet Dulaney Perkins Eye Center, Phoenix, AZ, USA; 7Ophthalmology Division, Creighton University School of Medicine, Phoenix, Arizona, USACorrespondence: Jordan M Graff, Barnet Dulaney Perkins Eye Center, Phoenix, AZ, USA, Tel +1 480 843 1868, Email JGraff@BDPEC.comPurpose: Faricimab, the first bispecific antibody designed for intraocular use, is approved for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). …”
    Get full text
    Article
  18. 238

    From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases by Qing Zhao, Linxin Wei, Youxin Chen

    Published 2025-03-01
    “…To date, active trials include treatments for primary open angle glaucoma with MYOC mutations, refractory herpetic viral keratitis, CEP290-associated inherited retinal degenerations, neovascular age-related macular degeneration, and retinitis pigmentosa with RHO mutations. …”
    Get full text
    Article
  19. 239

    Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen by Alexandra Miere, Hassiba Oubraham, Francesca Amoroso, Pauline Butori, Polina Astroz, Oudy Semoun, Elsa Bruyere, Alexandre Pedinielli, Manar Addou-Regnard, Camille Jung, Salomon Y. Cohen, Eric H. Souied

    Published 2018-01-01
    “…To compare the qualitative and quantitative choroidal neovascularization (CNV) changes after antivascular endothelial growth factor (anti-VEGF) therapy in treatment-naïve and treated eyes with age-related macular degeneration (AMD) using optical coherence tomography angiography (OCTA). …”
    Get full text
    Article
  20. 240